source
- Pfizer and Arvinas give disappointing breast cancer drug to RigelPfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. T…Endpoints · 3mo ago↗ source
- Bayer to make 'careful but aggressive' return to pharma M&A, CEO saysBayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-qu…Endpoints · 3mo ago↗ source
- Alkermes' narcolepsy Phase 3 success; Boehringer's antibody dealPlus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…